WallStSmart

Chemed Corp (CHE)vsHCA Healthcare, Inc. (HCA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 2907% more annual revenue ($76.39B vs $2.54B). CHE leads profitability with a 10.2% profit margin vs 8.9%. HCA appears more attractively valued with a PEG of 1.12. HCA earns a higher WallStSmart Score of 63/100 (C+).

CHE

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 7.5Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: 5.69

HCA

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CHE.

HCASignificantly Overvalued (-85.7%)

Margin of Safety

-85.7%

Fair Value

$286.26

Current Price

$372.13

$85.87 premium

UndervaluedFair: $286.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CHE3 strengths · Avg: 9.7/10
Return on EquityProfitability
30.6%10/10

Every $100 of equity generates 31 in profit

Altman Z-ScoreHealth
5.6910/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

HCA4 strengths · Avg: 9.3/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.9110/10

Conservative balance sheet, low leverage

Market CapQuality
$80.58B9/10

Large-cap with strong market position

P/E RatioValuation
12.5x8/10

Attractively priced relative to earnings

Areas to Watch

CHE4 concerns · Avg: 3.3/10
PEG RatioValuation
1.744/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-0.4%2/10

Earnings declined 0.4%

HCA2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CHE

The strongest argument for CHE centers on Return on Equity, Altman Z-Score, Debt/Equity.

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.12 suggests the stock is reasonably priced for its growth.

Bear Case : CHE

The primary concerns for CHE are PEG Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

HCA carries more volatility with a beta of 1.19 — expect wider price swings.

HCA is growing revenue faster at 4.3% — sustainability is the question.

HCA generates stronger free cash flow (895M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HCA scores higher overall (63/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chemed Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.

Visit Website →

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?